Clinical Trials Logo

Clinical Trial Summary

The main purpose of this study is to test the safety and efficacy of VS-4718 in two types of leukemia patients and to find the right dose of VS-4718 for future clinical trials.

Other purposes of this study include:

- Testing for study drug VS-4718 levels in blood over time and what happens to the study drug in patients.

- To find out if there are certain biomarkers in leukemia patients that predict if and how 4718 study drug may or may not work.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02215629
Study type Interventional
Source Verastem, Inc.
Contact
Status Withdrawn
Phase Phase 1
Completion date November 2016

See also
  Status Clinical Trial Phase
Terminated NCT04478695 - Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Terminated NCT05038800 - A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002) Phase 1
Completed NCT04176393 - A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation Phase 1
Recruiting NCT03850574 - Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Active, not recruiting NCT04666649 - Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) Phase 1
Recruiting NCT04842370 - Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML Phase 1
Active, not recruiting NCT02675452 - AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05522192 - Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia Phase 1/Phase 2
Completed NCT03755154 - Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Recruiting NCT05726110 - Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia Phase 3
Recruiting NCT03765541 - Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia Phase 3
Recruiting NCT05787496 - A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms Phase 1
Terminated NCT02623582 - CD123 Redirected Autologous T Cells for AML Early Phase 1